HEMODYNAMIC OPTIMIZATION AND ENDOTHELIAL STABILIZATION IN ISCHEMIC HEART DISEASE: A TARGETED CLINICAL PHARMACOLOGICAL APPROACH

Abstract

The progressive luminal narrowing and endothelial dysfunction inherent to ischemic heart disease require an aggressive, multi-targeted pharmacological blockade to prevent acute atherothrombotic events. This study evaluates the precise hemodynamic and metabolic outcomes of deploying a high-intensity, pleiotropic pharmacological regimen compared to conventional step-care angina management. A prospective clinical analysis was conducted involving 152 adult patients diagnosed with chronic coronary syndrome and stable angina pectoris. Subjects were stratified into two clinical pathways: a conventional therapy cohort (n=74) receiving standarddose beta-blockers and moderate-intensity statins, and a targeted aggressive therapy cohort (n=78) receiving maximum-tolerated antianginal combinations alongside high-intensity rosuvastatin and precise antiplatelet modulation. Clinical data indicate that standard, uncalibrated dosing frequently fails to arrest plaque progression or adequately suppress exercise-induced ischemia. The targeted cohort demonstrated a 62.4% relative reduction in weekly angina frequency by day 60, directly correlating with a profound suppression of low-density lipoprotein cholesterol to a mean of 1.3 ± 0.2 mmol/L. Conversely, the standard empirical group exhibited persistent anginal equivalents and a significantly higher rate of sublingual nitroglycerin dependency. The dynamics of the observed results suggest that isolated symptom palliation is critically insufficient for long-term myocardial preservation. Comprehensive pharmacotherapy must actively integrate aggressive lipid-lowering strategies and synergistic neurohormonal antagonists, individually calibrated against baseline resting heart rate and endothelial inflammatory markers, to successfully stabilize the atheromatous core and optimize coronary perfusion.